This is a prospective, open-label, single-arm pilot study treating 40 subjects to assess the
hypothesis that P2Y, G protein-coupled 12 (P2Y12) inhibition with Brilinta/ticagrelor (90 mg
by mouth (PO) twice a day) reduces episodic and/or chronic migraine headache symptoms in
patients with right to left shunt. Headache frequency while on Brilinta/ticagrelor will be
compared with the documented baseline for each subject. If the Brilinta/ticagrelor therapy
was effective (> 50% reduction in monthly headache days), the subject could elect to continue
therapy for an additional two months (56 days), while continuing to complete daily headache
logs.